Join us at World CB & CDx 2026
Tissue Intelligence for Biomarker
and CDx Development
Turn complex tissue biology into evidence for biomarker strategy, patient selection, and clinical development.
Panel discussion:
Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology
- Date: Wednesday, October 7, 2026
- Time: 2:10 PM EST
Panel Highlights:
- Tumor heterogeneity determines treatment response and resistance, and AI-powered computational pathology makes heterogeneity tractable for drug development.
- Tissue analysis succeeds in drug development when scientific, computational, and delivery expertise are integrated from the start, not assembled project by project.
- Connecting imaging features to outcomes to generate predictive biomarkers, and translating into cross-cohort and cross-platform validation and deployment.
- Infrastructure and global access shape which biomarkers can actually reach patients. H&E-based approaches can have an important role in ensuring equitable, global CDx access.
Moderator
Grainger Greene
VP, Product & Growth
Nucleai
Panelists
Ben Withey
Director, Commercial Diagnostics - CDx Lead
Pfizer
Sarah Hersey
VP, Head of Precision Medicine, Translational Sciences & Bioanalytical
Bristol Myers Squibb
Lauri Diehl, PhD
Executive Director, Research Pathology
Gilead Sciences
Sizun Jiang, PhD
Associate Professor
Harvard Medical School and Beth Israel Deaconess Medical Center
Book a Meeting with Us
Avi Veidman
CEO, Co-Founder
Byron Lawson
VP, Pharma BD & Strategic Partnerships
Grainger Greene
VP, Product & Growth
Sharon Elkobi
VP, Strategic Alliances & BD
Please complete the form below to schedule a meeting with our team at World CB & CDx 2026